Vyvanse (lisdexamfetamine) Letter of Medical Necessity
Vyvanse (lisdexamfetamine) PA decisions are increasingly driven by generic availability. LMNs should specify the indication and clinical rationale for brand or specific formulation.
FDA-Approved Indications
- ● ADHD in children ≥6 years and adults
- ● moderate-to-severe binge eating disorder in adults
Why Vyvanse Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Generic lisdexamfetamine preferred
- 2. Step therapy through methylphenidate
- 3. Cardiac risk not assessed
- 4. Quantity limit
What to Include in a Vyvanse Letter of Medical Necessity
Document ADHD diagnosis with rating scale, prior stimulant trials and outcomes, cardiac risk assessment, and rationale for lisdexamfetamine over alternatives.
Key clinical evidence to cite:
- ✓ Multiple ADHD pivotal trials
- ✓ Binge eating disorder trials (Studies 343, 344)
Relevant guidelines:
- 📖 AAP ADHD Guidelines
- 📖 AACAP ADHD Practice Parameters
Vyvanse Prior Authorization Criteria
Standard criteria across major US payers for Vyvanse. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy through methylphenidate
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Vyvanse
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Vyvanse Prior Authorization FAQ
Why was my Vyvanse prior authorization denied?
The most common denial reasons for Vyvanse are: Generic lisdexamfetamine preferred; Step therapy through methylphenidate; Cardiac risk not assessed; Quantity limit.
What should a Vyvanse Letter of Medical Necessity include?
Document ADHD diagnosis with rating scale, prior stimulant trials and outcomes, cardiac risk assessment, and rationale for lisdexamfetamine over alternatives.
Which payers cover Vyvanse?
Vyvanse is covered by major US payers including UnitedHealthcare, Aetna, Cigna, CVS Caremark, Express Scripts, though formulary tier and prior authorization criteria vary.